Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2014
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone; Dexamethasone
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 27 Dec 2012 Planned End Date changed from 1 Jun 2007 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 29 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.